Label: information for the user
Vosevi 400mg/100mg/100 mg film-coated tablets
sofosbuvir/velpatasvir/voxilaprevir
This medicine is subject to additional monitoring, which will facilitate the detection of new information about its safety. You can contribute by reporting any adverse effects you may experience. The final part of section4 includes information on how to report these adverse effects.
Read this label carefully before starting to take this medicine, as it contains important information for you.
-Keep this label, as you may need to refer to it again.
-If you have any doubts, consult your doctor or pharmacist.
-This medicine has been prescribed only for you, and you should not give it to others even if they have the same symptoms as you, as it may harm them.
-If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this label. See section4.
1.What is Vosevi and for what it is used
2.What you need to know before starting to take Vosevi
3.How to take Vosevi
4.Possible adverse effects
5.Storage of Vosevi
6.Contents of the package and additional information
Vosevi is a medication that contains the active ingredients sofosbuvir, velpatasvir, and voxilaprevir in a single tablet. It is administered to adults aged 18 years and older to treat a chronic (long-term) viral infection of the liver called hepatitis C.
The active ingredients of this medication act in combination to block three different proteins that the hepatitis C virus needs to grow and reproduce, which makes the infection eliminated from the body.
Do not take Vosevi
?If this is the case,do not take Vosevi and tell your doctor immediately.
Warnings and precautions
Consult your doctor if:
Consult your doctor or pharmacist before starting Vosevi if:
Consult your doctor immediatelyif you are currently taking or have taken in the past few months any medicine for heart problems and, during treatment, experience:
Blood tests
Your doctor will perform blood tests before, during, and after treatment with Vosevi. This is to:
Children and adolescents
Do not give this medicine to children and adolescents under 18years. Vosevi has not yet been studied in children and adolescents.
Other medicines and Vosevi
Inform your doctor or pharmacistif you are taking, have taken recently, or may need to take any other medicine.
If you are unsure, consult your doctor or pharmacist.
Some medicines should not be taken with Vosevi.Vosevi may not work properly or may worsen side effects if taken with them.
Inform your doctor or pharmacistif you are taking any of the following medicines:
Taking Vosevi with any of these medicines may prevent them from working properly or worsen their side effects. Your doctor may give you a different medicine or adjust the dose you are taking.
These medicines may reduce the amount of Vosevi in the blood. If you are taking any of these medicines, your doctor will give you a different medicine for stomach ulcers, heartburn, or acid reflux or recommend how and when to take it.
Pregnancy, breastfeeding, and fertility
If you are pregnant, think you may be pregnant, are breastfeeding, or plan to become pregnant, consult your doctor before using this medicine.
Pregnancy
Vosevi is not recommended during pregnancy.The effects of Vosevi during pregnancy are unknown.
Breastfeeding
Do not breastfeed during treatment with Vosevi.Some of the active ingredients in Vosevi may pass into breast milk.
Driving and using machines
Vosevi should not affect your ability to drive or use any tools or machinery.
Vosevi contains lactose
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Recommended dose
The recommended dose isonetabletoncedailyfor 8 or 12weeks.
Swallow the tablet whole with food. Do not chew, crush, or break the tablet, as it has a very bitter taste.
Renal problems
Ifyou have renal problemsor if you are receivingdialysistell your doctor, because Vosevi has not been fully evaluated in patients with severe renal problems.
Liver problems
You should not use Vosevi if you have moderate or severe liver problems.
If you are taking an antacid, take it at least 4hours before or at least 4hours after Vosevi.
If you vomit after taking Vosevithis may affect the amount of Vosevi in the blood. This may make Vosevi work less effectively.
If you take more Vosevi than you should
If you accidentally take a higher dose than the recommended doseof Vosevi, it may increase the risk of adverse effects of this medication (see section 4 Possible adverse effects).
You should contact your doctor or the nearest emergency service immediately for advice. Bring the tablet container with you to easily describe what you have taken.
If you forget to take Vosevi
It is essential not to miss any dose of this medication.
If you miss a dose, calculate how long it has been since you took the last Vosevi tablet:
Do not interrupt Vosevi treatment
Do not interrupt treatment with this medication unless your doctor tells you to. It is very important to complete the entire treatment cycle so that the medication is in the best conditions to treat the hepatitis C virus infection.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not all people will experience them.
Very Frequent Adverse Effects
(may affect more than 1 in 10 patients)
Frequent Adverse Effects
(may affect up to 1 in 10 patients)
Rare Adverse Effects
(may affect up to 1 in 100 people)
Other effects that may be observed during treatment with sofosbuvir:
The frequency of the following adverse effects is unknown (the frequency cannot be estimated from the available data).
-Severe generalized rash with skin peeling that may be accompanied by fever, flu-like symptoms, blisters in the mouth, eyes, and/or genitals (Stevens-Johnson syndrome).
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist,even if it is a possible adverse effect that does not appear in this prospectus.You can also report them directly through theSpanish System for Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es.By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the bottle and the box after “CAD”. The expiration date is the last day of the month indicated.
This medication does not require any special storage temperature..Store in the original packaging to protect it from moisture. Keep the bottle tightly closed.
Medicines should not be thrown down the drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. This way, you will help protect the environment.
Composition of Vosevi
Core of the tablet:
Colloidal anhydrous silica, copovidone, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose.
Film coating:
Iron oxide black (E172), iron oxide red (E172), iron oxide yellow (E172), macrogol, polyvinyl alcohol, talc, titanium dioxide (E171).
Appearance of the product and contents of the package:
The film-coated tablets are beige-colored, capsule-shaped tablets with "GSI" engraved on one side and "3" on the other. The tablet measures 20 mm in length and 10 mm in width.
The tablets are presented in plastic bottles with child-resistant caps. All bottles contain a desiccant with silica gel (desiccant) that must remain inside the bottle to protect the tablets. The desiccant with silica gel is in a separate bag or container that should not be swallowed.
The following package sizes are available:
Marketing Authorization Holder:
Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Ireland
Responsible for manufacturing:
Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland
To obtain more information about this medicinal product, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien Gilead Sciences Belgium SPRL-BVBA Tél/Tel: + 32 (0) 24 01 35 50 | Lietuva Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 |
???????? Gilead Sciences Ireland UC ???.: + 353 (0) 1 686 1888 | Luxembourg/Luxemburg Gilead Sciences Belgium SPRL-BVBA Tél/Tel: + 32 (0) 24 01 35 50 |
Ceská republika Gilead Sciences s.r.o. Tel: + 420 910 871 986 | Magyarország Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Danmark Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849 | Malta Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Deutschland Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0 | Nederland Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 98 |
Eesti Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 | Norge Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849 |
Ελλ?δα Gilead SciencesΕλλ?ςΜ.ΕΠΕ. Τηλ: + 30 210 8930 100 | Österreich Gilead Sciences GesmbH Tel: + 43 1 260 830 |
España Gilead Sciences, S.L. Tel: + 34 91 378 98 30 | Polska Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 |
France Gilead Sciences Tel.: + 33 (0) 1 46 09 41 00 | Portugal Gilead Sciences, Lda. Tel: + 351 21 7928790 |
Hrvatska Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | România Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Ireland Gilead Sciences Ireland UC Tel: +353 (0) 214 825 999 | Slovenija Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Ísland Gilead Sciences Sweden AB Sími: + 46 (0) 8 5057 1849 | Slovenská republika Gilead Sciences Slovakia s.r.o. Tel: + 421 232 121 210 |
Italia Gilead Sciences S.r.l. Tel: + 39 02 439201 | Suomi/Finland Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1849 |
Κ?προς Gilead SciencesΕλλ?ςΜ.ΕΠΕ. Τηλ: + 30 210 8930 100 | Sverige Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Latvija Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 | United Kingdom Gilead Sciences Ltd. Tel: + 44 (0) 8000 113 700 |
Last revision date of this leaflet:
The detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.